Launches·October 13, 2026 at 2:51 PM EDT·1 source
Novartis quietly returns a key antibiotic to US market
NVS -3.3%
NVS · last 30 trading days+5.1% since the news
News
What happened
- Novartis received supplemental FDA approval for Lamprene over the summer.
- The decades-old leprosy drug is transitioning to the US commercial market.
Why it matters
The approval could affect antibiotic commercialization and the healthcare market by bringing an established drug back to commercial distribution.
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
Who is involved
Novartis quietly returns a key antibiotic to US marketNovartisNVSFDALamprene
CompanyAgency
Sources (1)
- Endpoints NewsOct 13Novartis quietly returns a key antibiotic to US market
Related
- Oct 23 · Bristol Myers reveals autoimmune CAR-T trial death, explains summertime pause
- Oct 23 · Novartis multiple sclerosis treatment cuts rates of relapse in pivotal trials
- Oct 23 · Novartis Multiple Sclerosis Pill Missed Expectations in Key Study
- Oct 23 · Novartis’ Kisqali Cuts Death Risk 19% in Breast Cancer Study
- Oct 22 · Roche talks up Phase 3 success rate as it unveils pipeline cuts
- Oct 16 · Novartis scraps Fabhalta study in lupus nephritis
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
- Why it matters to youEvery story matched to your watchlist, your contacts and your pipeline.
- Follow developing storiesAn alert, and a push, the moment a story you follow moves.
- Your briefing, read aloudA few minutes each morning with a chapter per story.
- Brief modeSwipe through the day, a 20-second card each.